Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial.

•Alirocumab 150 mg Q2W reduced low-density lipoprotein cholesterol (LDL-C) by 63.1% at Week 8 of LONG TERM trial (HeFH cohort).•Alirocumab 75 mg Q2W reduced LDL-C by 47.3% at Week 8 of OLE (same cohort, n = 214).•Choice of alirocumab dose allowed for an individualized approach to LDL-C lowering.•Alirocumab provided steady LDL-C reductions over ≤3 years of treatment.•Treatment-emergent adverse events leading to treatment discontinuation occurred in 4 patients (1.9%)